NCT06290102View on ClinicalTrials.gov

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

October 1, 2024

Study Completion Date

October 7, 2024

Conditions
Asthma
Interventions
DRUG

TEV-56248

"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"

DRUG

Fp MDPI

"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"

Trial Locations (10)

33130

Teva Investigational Site 12007, Miami

33142

Teva Investigational Site 12005, Miami

33155

Teva Investigational Site 12002, Miami

36608

Teva Investigational Site 12010, Mobile

65203

Teva Investigational Site 12011, Columbia

70508

Teva Investigational Site 12008, Lafayette

78006

Teva Investigational Site 12001, Boerne

78249

Teva Investigational Site 12009, San Antonio

90815

Teva Investigational Site 12003, Long Beach

73120-9389

Teva Investigational Site 12012, Oklahoma City

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT06290102 - Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old | Biotech Hunter | Biotech Hunter